Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Azacitidine 41Cytarabine 27fludarabine phosphate 25Cyclophosphamide 23venetoclax 21fludarabine 21Peripheral Blood Stem Cell Transplantation 20Mycophenolic Acid 17Filgrastim 17Decitabine 17Tacrolimus 16Whole-Body Irradiation 15ruxolitinib 14Cyclosporine 14Busulfan 14Melphalan 12Methotrexate 10Imatinib Mesylate 10Stem Cell Transplantation 9Antilymphocyte Serum 8Alemtuzumab 8nilotinib 7decitabine and cedazuridine drug combination 7Granulocyte Colony-Stimulating Factor 7Rituximab 6Injections 6Idarubicin 6Dasatinib 6Clofarabine 6AP 1903 reagent 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × seclidemstat × Myeloid × Clear all
NCT04734990 2026-04-02

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
24 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡